JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.
Skip to content
Characteristics
Phase 2 randomized controlled trial
Peer reviewed
Duration
Four weekly doses
Topics
PTSD
Keywords
Placebo
Adverse effect
Phase matter
Posttraumatic stress
Clinical psychology
Key findings
TSND-201 significantly reduced PTSD symptoms compared with placebo over four weekly doses.
Abstract
Four weekly doses of TSND‐201 (methylone), an analog of 3,4 methylenedioxymethamphetamine (MDMA), resulted in significant improvement relative to placebo in reducing symptoms of post‐traumatic stress disorder (PTSD), a Phase 2 study has found. Treatment‐emergent adverse events associated with TSND‐201 were generally mild to moderate in severity, with no significant suicidal ideation. Study results were published online Feb. 18, 2026, in JAMA Psychiatry .
Comparable studies
Other randomized controlled trials on
PTSD , most cited first.
Study
Year
Design
Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Patients with severe PTSD, including those with comorbidities such as dissociation,...
2021
Randomized controlled trial
n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Patients with chronic post-traumatic stress disorder refractory to both psychotherapy...
2010
Randomized controlled trial
n = 20
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder
Patients with chronic PTSD related to a range of trauma exposures
2014
Randomized controlled trial
n = 41
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Military veterans and first responders aged 18 or older with chronic PTSD lasting 6...
2018
Randomized, double-blind, dose-response, phase 2 clinical trial
n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)
Patients with treatment-resistant PTSD
2012
Randomized controlled trial
n = 12
Create a free account to bookmark articles, vote on relevance, generate your own syntheses, and join the discussion.
For research and education, not medical advice. Talk with a clinician about your own care.
© 2026 The Consciousness Library
Support Our Mission
Choose your preferred way to support The Consciousness Library's work in advancing consciousness research.
A registered 501(c)(3) nonprofit; donations are tax-deductible in the US.
Donations are processed by Mindscape Collective, our legal entity, and may appear that way on your statement.